gemc: collagen vascular disease: considerations for emergent management: resident training
Post on 19-Oct-2014
1.649 views
DESCRIPTION
This is a lecture by Dr. Joseph Hartmann from the Ghana Emergency Medicine Collaborative. To download the editable version (in PPT), to access additional learning modules, or to learn more about the project, see http://openmi.ch/em-gemc. Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Share Alike-3.0 License: http://creativecommons.org/licenses/by-sa/3.0/.TRANSCRIPT
![Page 1: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/1.jpg)
Project: Ghana Emergency Medicine Collaborative Document Title: Collagen Vascular Disease: Considerations for Emergent Management Author(s): Joseph Hartmann, D.O., 2012 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Share Alike-3.0 License: http://creativecommons.org/licenses/by-sa/3.0/
We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. These lectures have been modified in the process of making a publicly shareable version. The citation key on the following slide provides information about how you may share and adapt this material. Copyright holders of content included in this material should contact [email protected] with any questions, corrections, or clarification regarding the use of content. For more information about how to cite these materials visit http://open.umich.edu/privacy-and-terms-use. Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition. Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.
1
![Page 2: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/2.jpg)
Attribution Key
for more information see: http://open.umich.edu/wiki/AttributionPolicy
Use + Share + Adapt
Make Your Own Assessment
Creative Commons – Attribution License
Creative Commons – Attribution Share Alike License
Creative Commons – Attribution Noncommercial License
Creative Commons – Attribution Noncommercial Share Alike License
GNU – Free Documentation License
Creative Commons – Zero Waiver
Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ
Public Domain – Expired: Works that are no longer protected due to an expired copyright term.
Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105)
Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain.
Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that your use of the content is Fair. To use this content you should do your own independent analysis to determine whether or not your use will be Fair.
{ Content the copyright holder, author, or law permits you to use, share and adapt. }
{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }
{ Content Open.Michigan has used under a Fair Use determination. }
2
![Page 3: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/3.jpg)
Collagen Vascular Disease -Considerations for Emergent
Management
Joseph H. Hartmann, D.O.
3
![Page 4: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/4.jpg)
Emergent Management ???
• Chronic conditions with long-term management decisions made by others
but • Because of their chronicity they present with
- flares of general disease process - end-organ involvement
• Occasionally determine the initial diagnosis
4
![Page 5: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/5.jpg)
Where are you taking me today?
• Raynaud phenomenon • Reactive arthritis (Reiter Syndrome) • Rheumatoid arthritis • Systemic sclerosis (Scleroderma) • Systemic lupus erythematosus • Polymyalgia rheumatica • Polymyositis / Dermatomyositis • Vasculitides
5
![Page 6: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/6.jpg)
Raynaud Phenomenon
• Definition: – Exaggerated vasospasm of digital / precapil-
lary arteries of fingers, toes, ears, nose, knees and nipples
– Initiated by exposure to cold or emotional stress
6
![Page 7: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/7.jpg)
Raynaud Phenomenon
• Etiology: – Unknown – May be first precursor of future connective
tissue disorder • Clinical Presentation:
– Triphasic – Typically begins in one finger then symmetric-
ally spreads to other fingers but usually spares the thumb
7
![Page 8: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/8.jpg)
Raynaud Phenomenon
• Triphasic progression – White – pallor
• Lack of arterial flow due to vasospasm
– Blue • Cyanosis from blood pooling
– Red • Reactive hyperemia
– Ischemic phases (white-blue) last 15-20 min 8
![Page 9: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/9.jpg)
National Heart, Lung, and Blood Institute, Wikimedia Commons
9
![Page 10: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/10.jpg)
Intermedichbo, Wikimedia Commons
10
![Page 11: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/11.jpg)
Niklas D, Wikimedia Commons
11
![Page 12: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/12.jpg)
Raynaud Phenomenon
• Relative temperature shifts may be provocative
• General body chill can trigger
• Fear / anxiety can trigger
12
![Page 13: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/13.jpg)
Raynaud Phenomenon
• Specific criteria – Symmetric episodic attacks – No evidence of peripheral vascular disease – No tissue gangrene, digital pitting, or tissue
injury – Negative nailfold capillary examination – Negative ANA, normal ESR
13
![Page 14: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/14.jpg)
Raynaud Phenomenon
• Nailfold capillary microscopy – – Place drop of immersion oil on periungual
area then examine with ophthalmoscope set at diopter 40 or a dissecting microscope.
– Should see regularly spaced capillary loops – Abnormal findings –
• Enlarged or distorted capillary loops • Relative paucity of loops
14
![Page 15: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/15.jpg)
Source Undetermined Source Undetermined
15
![Page 16: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/16.jpg)
Source Undetermined 16
![Page 17: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/17.jpg)
Source Undetermined 17
![Page 18: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/18.jpg)
Raynaud Phenomenon
• Treatment – Avoidance strategies
• Cold, nicotine, sympathomimetics (decongestants, diet pills, herbs containing ephedra)
– Drug therapy • Ca channel blockers, direct vasodilators (NTG,
hydralazine, minoxidil), sympatholytics (methyldopa, reserpine, prazosin), prostaglandins, anticoagulation / antithrombotic tx (aspirin, dipyrid-amole, heparin, LMWH)
• sympathectomy 18
![Page 19: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/19.jpg)
Raynaud Phenomenon • Severe ischemia
– Warm patient (body and digits) – Analgesics – Antiplatelet tx – aspirin – Vasodilator tx
• Nifedipine extended release 30-60 mg daily • Amlodipine 5-10 mg daily
– Topical NTG – Heparin / LMWH 24-72 hrs – Temporary chemical sympathectomy
• Digital or regional block – lidocaine/bupivicaine
– IV prostaglandin administration 19
![Page 20: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/20.jpg)
Reactive Arthritis (Reiter Syndrome)
• Definition: – Arthritis following a preceding infection without
intra-articular presence of the pathogen i.e. not a septic joint
• Etiology: – Seronegative (rheumatoid factor negative) – Spondyloarthropathy (very likely HLA-B27 pos) – Follows a GU or GI infection
20
![Page 21: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/21.jpg)
Reactive Arthritis
• Clinical Presentation: – Male 15 – 35 y/o – Asymmetric, oligoarthritis (2-4 joints) – Usually involves lower extremeties and sacroiliac
joints – Skin lesions resembling pustular psoriasis on
palms and soles – keratoderma blennorrhagicum – lesions on glans penis – balanitis circinata
21
![Page 22: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/22.jpg)
Centers for Disease Control and Prevention, Wikimedia Commons 22
![Page 23: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/23.jpg)
Source Undetermined Source Undetermined
23
![Page 24: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/24.jpg)
Reactive Arthritis
• Classic triad of Reiter syndrome – Nongonococcal urethritis (Chlamydia) – Conjunctivitis / anterior uveitis – Arthritis
• Following GI infection with Shigella, Sal-monella, Campylobacter, Yersinia, Clost-ridium difficile (?)
• Infection precedes arthritis by 2 - 6 wk
24
![Page 25: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/25.jpg)
Reactive Arthritis
• Treatment: – NSAIDs
• Naproxen 500 mg TID • Indomethacin 50 mg TID
– Intra-articular glucocorticoids – Expect resolution 3 – 12 months
25
![Page 26: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/26.jpg)
Rheumatoid Arthritis
• Definition: – Chronic, symmetric polyarticular synovial joint
disease • Nonarticular & Systemic Manifestations
– HEENT • Episcleritis
– Painless injection of episcleral vessels (self-limiting)
• Scleritis – Dark red / purple discoloration with marked ocular
tenderness – Potential for visual impairment and scleral rupture 26
![Page 27: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/27.jpg)
Source Undetermined
Source Undetermined 27
![Page 28: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/28.jpg)
Source Undetermined
Source Undetermined 28
![Page 29: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/29.jpg)
Rheumatoid Arthritis
• Cricoarytenoid joint – Dysphonia, hoarseness, stridor – If fix in closed position could require emergent
tracheostomy • Ligamentous destruction of transverse
ligament of C-2 with potential for cord compression
29
![Page 30: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/30.jpg)
Rheumatoid Arthritis
• Pulmonary – Pleural effusion * – Interstitial fibrosis – Pulmonary nodules
• Cardiac – Pericarditis * – Pericardial effusion 10% – Myocarditis – CAD – sudden death, MI *
30
![Page 31: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/31.jpg)
Rheumatoid Arthritis
• Renal – Focal glomerulonephropathy – Drug toxicity from treatment *
• Vasculitis – Distal infarcts, ulcerations, gangrene
• CNS – Generally spared
31
![Page 32: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/32.jpg)
Systemic Sclerosis - Scleroderma
• Definition: – Disease process characterized by progressive
fibrosis, vascular abnormalities and inflamma-tory processes that can be manifested quite locally or diffusely systematically with organ system involvement
• Etiology: – Poorly understood
32
![Page 33: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/33.jpg)
Systemic Sclerosis
• Clinical Presentation: – Often initial signs are a thickening, hardening
of the skin, usually fingers, hands and face and Raynaud phenomenon
– Female > Male – African-Americans tend to have worse
prognosis due to greater likelihood of having a more severe diffuse form
33
![Page 34: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/34.jpg)
Systemic Sclerosis
• Skin – Sclerodactyly – Telangiectasias – Digital ulcers – Calcinosis – Raynaud phenomenon
34
![Page 35: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/35.jpg)
Source Undetermined
In scleroderma, the abnormal build-up of fibrous tissue in the skin can cause the skin to tighten so severely that the fingers curl and lose their mobility.
35
![Page 36: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/36.jpg)
Telangiectasia
Dilation of small vessels and capillaries cause flat red marks to appear on the skin
Kerry J, Flickr
36
![Page 37: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/37.jpg)
Jmh649, Wikimedia Commons
37
![Page 38: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/38.jpg)
Source Undetermined
38
![Page 39: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/39.jpg)
Source Undetermined
39
![Page 40: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/40.jpg)
Systemic Sclerosis • Pulmonary
– Most common cause of death – Interstitial lung disease
• Alveolitis leading to eventual fibrosis
– Pulmonary vascular disease • Pulmonary hypertension
• Cardiac – Pericarditis w/wo effusion – Myocardial fibrosis
• Resultant ventricular dysfunction with diminished cardiac output
– Dysrhythmias • Fibrosis of conduction system resulting in sudden death
40
![Page 41: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/41.jpg)
Systemic Sclerosis • Renal
– Renal crisis • Acute onset of renal failure • Proteinuria and microscopic hematuria • Abrupt onset of hypertensive emergency
• Gastrointestinal – Hypomobility
• Esophageal dysmotility / GERD • Pseudo-obstruction, constipation • Teleangectasias with bleeding • Pneumatosis intestinalis
41
![Page 42: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/42.jpg)
Lipothymia, Wikimedia Commons
42
![Page 43: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/43.jpg)
Source Undetermined
Source Undetermined
43
![Page 44: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/44.jpg)
Systemic Sclerosis • Treatment
– Generally immunosuppressive therapy – Based on specific organ system involved – Emergently
• Pulmonary decompensation • Cardiac – effusion, failure, dysrhythmia • Renal crisis
– ACE inhibitor is first line antihypertensive agent – Captopril – Captopril + Ca channel blocker – Angiotensin receptor blocker for those who can not tolerate
ACE inhibitor
44
![Page 45: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/45.jpg)
Systemic Lupus Erythematosus
• Definition: – Chronic autoimmune disease characterized by
presence of autoantibodies with multi-organ system involvement
• Etiology: – Genetic predisposition and nebulous factors
combine to alter immune cell function resulting in production of autoantigens and thereby auto-antibodies with systemic consequences.
45
![Page 46: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/46.jpg)
SLE • Clinical Presentation:
– Female > Male 10 : 1 – Typical presentation 21 – 45 yrs of age – African American > Caucasians – Constitutional
• Wt loss, fever, myalgias, arthralgias • Fatigue often the most debilitating
– Skin • Butterfly malar rash – may be fleeting • Oral and nasal ulcerations
46
![Page 47: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/47.jpg)
Source Undetermined
Source Undetermined
Source Undetermined
47
![Page 48: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/48.jpg)
SLE • Pulmonary
– Pleurisy, effusion, interstitial lung disease, pulmonary hypertension
– “lupus lung” – alveolar hemorrhage • Cardiac
– Pericarditis *, effusion – Increased risk for CAD
• Renal – Lupus nephritis
• Elevated creatinine, proteinuria, hypertension 48
![Page 49: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/49.jpg)
SLE
• Neurologic – Cognitive defects, cephalgia, seizures,
peripheral neuropathies (stocking / glove), psychosis, stroke (antiphospholipid antibody syndrome)
• Musculoskeletal – Arthritis, atrophy, tendon rupture
49
![Page 50: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/50.jpg)
SLE • Treatment:
– Immunosuppression • Glucocorticoids • Methotrexate, cyclophosphamide, azathioprine,
mycophenolate, rituximab – Causes of death
• Early deaths – first few years – Active lupus (cardiac, renal, CNS dz) – Infection due to immunosuppression
• Late deaths – Chronic effects of lupus (ESRD, CAD) – Infection, malignancy
50
![Page 51: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/51.jpg)
Polymyalgia Rheumatica
• Definition: – Rheumatic condition frequently associated
with giant cell (temporal) arteritis • Etiology:
– Genetic predisposition – Relatively common – 50% of pts with GCA will develop PMR – 15% of pts with PMR will develop GCA
51
![Page 52: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/52.jpg)
Polymyalgia Rheumatica
• Clinical Presentation: – Age 50 or older at onset – Bilateral aching and morning stiffness which
lasts 30 min or more for 1 month or more involving at least 2 of 3 areas
• Neck or torso • Shoulders or proximal arms • Hips or proximal thighs
– ESR = 40 mm/hr or greater
52
![Page 53: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/53.jpg)
Polymyalgia rheumatica
Original Image: Twisp, Wikimedia Commons Modified Image Lena Carleton, University of Michigan 53
![Page 54: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/54.jpg)
Source Undetermined
Giant Cell Arteritis
54
![Page 55: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/55.jpg)
Polymyalgia Rheumatica
• treatment: – Prednisone 10 – 20 mg / day
• (compared to 60 mg / day dose for GCA)
– Rapid response is characteristic (often after first dose)
– Relapse is commonly seen requiring increase in prednisone
55
![Page 56: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/56.jpg)
Polymyositis / Dermatomyositis
• Definition: – Idiopathic inflammatory myopathies
• Etiology: – Genetic component with presumed environ-
mental triggers – Peak incidence between 40 – 50 yrs of age – Female : Male 2 : 1
56
![Page 57: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/57.jpg)
Polymyositis / Dermatomyositis • Clinical Presentation:
– Muscle weakness • Onset is insidious • Gradually worsening over months • Typically symmetric and proximal
– Myalgias / muscle tenderness occurs in 25-50% but is mild compared to PMR or fibromyalgia
– Dermatologic findings in DM • Gottron’s sign
– Erythematous, often scaly exanthem occurring symmetrically over MCP and IP joints and / or over extensor surfaces of elbows and knees resembling psoriasis
57
![Page 58: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/58.jpg)
Madhero88, Wikimedia Commons
Madhero88, Wikimedia Commons
58
![Page 59: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/59.jpg)
Polymyositis / Dermatomyositis – Heliotrope rash
• Violaceous eruption on upper eyelids, often with swelling
– Shawl sign and V sign • Diffuse flat erythematous lesion over chest and
shoulders (shawl sign) or over anterior neck and chest (V sign)
– Erythroderma • Extensive areas of skin redness (malar, forehead)
– Mechanic’s hands (DM or PM) • Rough, cracking skin at tips and lateral aspects of
fingers with irregular dirty appearing lines 59
![Page 60: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/60.jpg)
Madhero, Wikimedia Commons
60
![Page 61: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/61.jpg)
Madhero88, Wikimedia Commons
61
![Page 62: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/62.jpg)
Source Undetermined
Source Undetermined 62
![Page 63: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/63.jpg)
Polymyositis / Dermatomyositis • Diagnostic testing
– Elevated CK, LDH, aldolase, aminotransferases • Increased incidence of malignancy
associated with dermatomyositis • Treatment:
– Glucocorticoid regimen • initiate with high doses for several months to
establish disease control • Slow taper to lowest effective dose for 9 – 12 months
– Glucocorticoid-sparing regimen • Azathoprine / methotrexate 63
![Page 64: GEMC: Collagen Vascular Disease: Considerations for Emergent Management: Resident Training](https://reader033.vdocuments.us/reader033/viewer/2022052503/5443f1dfb1af9f680a8b46db/html5/thumbnails/64.jpg)
Vasculitides • Large vessel
– Takayasu arteritis – Giant cell (temporal) arteritis
• Medium vessel – Polyarteritis nodosa – Kawasaki disease
• Small vessel – Churg-Strauss arteritis – Wegener’s granulomatosis – Henoch-Schonlein purpura 64